3 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Turcot syndrome: new trials by email Literature Review of Turcot syndrome trials Research Report on Turcot syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types MT-8421, Nivolumab - Non Small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 1 | Terminated | Molecular Templates, Inc. | 15 | 2023-11-01 | 2024-11-01 |
| Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors INCB 99280 with Ipilimumab - Melanoma, Hepatocellular Carcinoma (HCC) | Phase 1 | Terminated | Incyte Corporation | 8 | 2023-08-29 | 2025-02-18 |
| Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers Nivolumab - Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients | Phase 1 / Phase 2 | Terminated | The Hospital for Sick Children | 11 | 2017-05-15 | 2026-11-05 |
Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Mesothelioma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Kidney Diseases (2) · Kidney Neoplasms (2) · Liver Diseases (2) · Liver Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Nivolumab (2) · Ipilimumab (1)
Incyte Corporation (1) · Molecular Templates, Inc. (1) · The Hospital for Sick Children (1)
United States (3) · Canada (2) · Australia (1) · France (1) · Israel (1) · South Africa (1)
Admasu Mamuye, MD (1) · Daniel A Morgenstern, MB BChir PhD (1)
2023 (1)